All Relations between asymmetrical (pato 0000616) and nitrogen monoxide

Reference Sentence Publish Date Extraction Date Species
J T Kielstein, S Simmel, S M Bode-B\\xc3\\xb6ger, H J Roth, H Schmidt-Gayk, H Haller, D Flise. Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney & blood pressure research vol 27 issue 3 2005 15192321 increased blood concentrations of the endogenous nitric oxide (no) synthase inhibitor asymmetric dimethylarginine (adma) have been linked to high blood pressure and to cardiovascular mortality. 2005-02-08 2022-01-12 Not clear
Robert J Nijveldt, Michiel P C Siroen, Tom Teerlink, Antonie A van Lambalgen, Jan A Rauwerda, Paul A M van Leeuwe. Gut and liver handling of asymmetric and symmetric dimethylarginine in the rat under basal conditions and during endotoxemia. Liver international : official journal of the International Association for the Study of the Liver vol 24 issue 5 2005 15482350 asymmetric dimethylarginine (adma) is an endogenous inhibitor of nitric oxide (no) synthase enzymes, whereas symmetric dimethylarginine (sdma) competes with arginine transport. 2005-02-01 2022-01-12 Not clear
Paloma Lluch, Bel\\xc3\\xa9n Torondel, Pascual Medina, Gloria Segarra, Juan A Del Olmo, Miguel A Serra, Jos\\xc3\\xa9 M Rodrig. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. Journal of hepatology vol 41 issue 1 2005 15246208 plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. 2005-01-31 2022-01-12 Not clear
Paloma Lluch, Bel\\xc3\\xa9n Torondel, Pascual Medina, Gloria Segarra, Juan A Del Olmo, Miguel A Serra, Jos\\xc3\\xa9 M Rodrig. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. Journal of hepatology vol 41 issue 1 2005 15246208 the liver plays a prominent role in the metabolism of asymmetric dimethyl-l-arginine (adma), an endogenous inhibitor of nitric oxide (no) synthase. 2005-01-31 2022-01-12 Not clear
Jens Martens-Lobenhoffer, Olga Krug, Stefanie M Bode-B\\xc3\\xb6ge. Determination of arginine and asymmetric dimethylarginine (ADMA) in human plasma by liquid chromatography/mass spectrometry with the isotope dilution technique. Journal of mass spectrometry : JMS vol 39 issue 11 2005 15472999 arginine (arg) is a substrate for endogenous nitric oxide (no) production whereas its metabolite, asymmetric dimethylarginine (adma), acts as an inhibitor. 2005-01-03 2022-01-12 Not clear
Shin Takiuchi, Hideki Fujii, Kei Kamide, Takeshi Horio, Satoshi Nakatani, Aki Hiuge, Hiromi Rakugi, Toshio Ogihara, Yuhei Kawan. Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. American journal of hypertension vol 17 issue 9 2004 15363823 we hypothesized that changes in serum asymmetric dimethylarginine (adma), an endogenous inhibitor of nitric oxide synthase, and concomitant insulin resistance may be underlying factors connecting the two pathologic alterations. 2004-12-16 2022-01-12 Not clear
J T Kielstein, R H B\\xc3\\xb6ger, S M Bode-B\\xc3\\xb6ger, J Martens-Lobenhoffer, G Lonnemann, J C Fr\\xc3\\xb6lich, H Haller, D Flise. Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro evidence of significant protein binding. Clinical nephrology vol 62 issue 4 2004 15524060 increased blood levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (adma) predict cardiovascular mortality in patients with end-stage renal disease. 2004-12-15 2022-01-12 Not clear
Carla S Jung, Brian A Iuliano, Judith Harvey-White, Michael G Espey, Edward H Oldfield, Ryszard M Plut. Association between cerebrospinal fluid levels of asymmetric dimethyl-L-arginine, an endogenous inhibitor of endothelial nitric oxide synthase, and cerebral vasospasm in a primate model of subarachnoid hemorrhage. Journal of neurosurgery vol 101 issue 5 2004 15543672 association between cerebrospinal fluid levels of asymmetric dimethyl-l-arginine, an endogenous inhibitor of endothelial nitric oxide synthase, and cerebral vasospasm in a primate model of subarachnoid hemorrhage. 2004-12-07 2022-01-12 Not clear
Zhong Dai, Hui-Qing Zhu, De-Jian Jiang, Jun-Ling Jiang, Han-Wu Deng, Yuan-Jian L. 17beta-estradiol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. International journal of cardiology vol 96 issue 2 2004 15262037 the purpose of the present study was to investigate the effect of estradiol on endothelial dysfunction and the increased level of asymmetric dimethylarginine (adma), an endogenous nitric oxide synthase inhibitor, induced by ldl. 2004-12-01 2022-01-12 Not clear
Joseph Loscalz. L-arginine and atherothrombosis. The Journal of nutrition vol 134 issue 10 Suppl 2004 15465788 the mechanisms by which l-arginine improves endothelial nitric oxide bioactivity include increased intracellular uptake via the high-affinity cationic transporter; substrate competition with asymmetric dimethylarginine, a naturally occurring inhibitor of nitric oxide synthase; direct antioxidant activity; stimulated release of histamine from mast cells, which produces a vasodilator response; decreased activity of norepinephrine, which promotes the effect of endogenous vasodilators including nitric oxide; and increased insulin secretion, which causes vasodilation. 2004-11-23 2022-01-12 Not clear
Rainer H B\\xc3\\xb6ge. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the \"L-arginine paradox\" and acts as a novel cardiovascular risk factor. The Journal of nutrition vol 134 issue 10 Suppl 2004 15465797 asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "l-arginine paradox" and acts as a novel cardiovascular risk factor. 2004-11-23 2022-01-12 Not clear
Robert J Nijveldt, Michiel P C Siroen, Tom Teerlink, Paul A M van Leeuwe. Elimination of asymmetric dimethylarginine by the kidney and the liver: a link to the development of multiple organ failure? The Journal of nutrition vol 134 issue 10 Suppl 2004 15465798 asymmetric dimethylarginine (adma) is a recently recognized endogenous inhibitor of nitric oxide production. 2004-11-23 2022-01-12 Not clear
De-Jian Jiang, Jun-Lin Jiang, Hui-Qing Zhu, Gui-Shan Tan, Shao-Qian Liu, Kang-Ping Xu, Yuan-Jian L. Demethylbellidifolin preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Journal of ethnopharmacology vol 93 issue 2-3 2004 15234768 the relationship between the protective effects of dmb on endothelium and the level of asymmetric dimethylarginine (adma), an endogenous inhibitor of nitric oxide synthase, was also determined in the present study. 2004-11-16 2022-01-12 Not clear
Patrick Vallance, James Leipe. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arteriosclerosis, thrombosis, and vascular biology vol 24 issue 6 2004 15105281 an increasing number of reports indicate that endogenously produced inhibitors of nitric oxide synthase, particularly asymmetric dimethylarginine (adma), regulate nitric oxide generation in disease states. 2004-11-08 2022-01-12 Not clear
Jutta Dierkes, Sabine Westphal, Jens Martens-Lobenhoffer, Claus Luley, Stefanie M Bode-B\\xc3\\xb6ge. Fenofibrate increases the L-arginine:ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration. Atherosclerosis vol 173 issue 2 2004 15064097 asymmetric dimethylarginine (adma), a guanidino-substituted analogue of l-arginine, is a potent endogenous competitive inhibitor of the endothelial nitric oxide synthase and therefore a potentially atherogenic amino acid. 2004-10-05 2022-01-12 Not clear
Lise Tarnow, Peter Hovind, Tom Teerlink, Coen D A Stehouwer, Hans-Henrik Parvin. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes care vol 27 issue 3 2004 14988299 increased plasma concentration of asymmetric dimethylarginine (adma), an endogenous inhibitor of nitric oxide synthase, has been associated with endothelial dysfunction, insulin resistance, and atherosclerosis in nondiabetic populations. 2004-09-23 2022-01-12 Not clear
Michael L Selle. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. Journal of affective disorders vol 80 issue 2-3 2004 15207938 increased (e)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. 2004-09-23 2022-01-12 Not clear
Michael L Selle. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. Journal of affective disorders vol 80 issue 2-3 2004 15207938 asymmetric dimethylarginine (adma) is an endogenous inhibitor of endothelial nitric oxide synthase (nos). 2004-09-23 2022-01-12 Not clear
Jens Martens-Lobenhoffer, Stefanie M Bode-B\\xc3\\xb6ge. Simultaneous detection of arginine, asymmetric dimethylarginine, symmetric dimethylarginine and citrulline in human plasma and urine applying liquid chromatography-mass spectrometry with very straightforward sample preparation. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences vol 798 issue 2 2004 14643502 nitric oxide (no) is synthesized by no synthase from l-arginine, which can be competitively blocked by endogenous inhibitors such as asymmetric dimethylarginine (adma), but not by symmetric dimethylarginine (sdma). 2004-09-20 2022-01-13 Not clear
Francesca Mallamaci, Giovanni Tripepi, Renke Maas, Lorenzo Malatino, Rainer B\\xc3\\xb6ger, Carmine Zoccal. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. Journal of the American Society of Nephrology : JASN vol 15 issue 2 2004 14747391 high sympathetic activity and alterations in nitric oxide synthesis attributable to accumulation of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (adma) have recently been identified as potential causal mechanisms for the high cardiovascular mortality rates among patients with esrd. 2004-09-20 2022-01-12 Not clear
Page: 
1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25   26   27   28   29   30   31   32   33   34   35   36   37   38   39   40   41   42   43   44   45   46   47   48   49   50   51   52   53   54